UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/572,827	03/07/2007	Kenneth Feldmann	2750-1573PWO1	5253
	7590 11/17/200 ART KOLASCH & BI	EXAMINER		
PO BOX 747	CH 111 22010 0717	BAUM, STUART F		
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
			1638	
			NOTIFICATION DATE	DELIVERY MODE
			11/17/2009	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

	Application No.	Applicant(s)					
Office Action Occurrence	10/572,827	FELDMANN ET AL.					
Office Action Summary	Examiner	Art Unit					
	STUART F. BAUM	1638					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ Responsive to communication(s) filed on <u>07 Ma</u>	arch 2007.						
	action is non-final.						
<i>i</i> —	, _						
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-20</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7) Claim(s) is/are objected to.							
·= · · ·	lection requirement						
8) Claim(s) <u>1-20</u> are subject to restriction and/or election requirement.							
Application Papers							
9)☐ The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) acce	10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the o	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some coll None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)	a> □ tatan ta a	(PTO 442)					
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date							
3) Information Disclosure Statement(s) (PTO/SB/08)							
Paper No(s)/Mail Date 6) Other: <u>blast search result</u> .							

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-9, 11-16 and 18-20, drawn to an isolated nucleic acid molecule which encodes an amino acid sequence; a vector, host cell, methods and plant comprising said nucleic acid molecule.

If Applicants elect Group I, Applicants are also to elect one DNA sequence from claim 2 and one corresponding amino acid sequence from claim 1, and one amino acid sequence from claim 4.

Group II, claim 10, drawn to an isolated polypeptide.

If Applicants elect Group II, Applicants are to elect one amino acid sequence from claim 10.

Group III, claim 17, drawn to a method for detecting a nucleic acid in a sample.

If Applicants elect Group III, Applicants are to elect one DNA sequence from claim 2 and a corresponding amino acid sequence from claim 1.

2. The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special

Art Unit: 1638

technical features for the following reasons: the nucleic acid capable of hybridizing toa nucleic acid according to any one of paragraphs (a) - (c) under conditions specified in claim 1(d) is taught in the prior art. Genoplante (July, 2003 NCBI Accession Number CD956065) teach a nucleic acid sequence that is capable of hybridizing to a sequence recited in claim 1(b) under conditions specified in claim 1(d) (sequence search result included).

- 3. In addition, the claims are not linked by a single technical feature because they are each drawn to products and processes not shared by the other. The nucleic acid of Group I is not shared by the protein of Group II which is not shared by the method of Group III.
- 4. Each of Inventions I-III are capable of being separately made, independently used and the patentability of one does not render the others obvious or unpatentable.
- 5. Because these inventions are distinct for the reasons given above, have acquired a separate status in the art as shown by the literature and sequence searches required for each of the Inventions are not required for another of the Inventions, restriction for examination purposes as indicated is proper.
- 6. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 7. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

Application/Control Number: 10/572,827 Page 4

Art Unit: 1638

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stuart F. Baum whose telephone number is 571-272-0792. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

/Stuart F. Baum/ Stuart F. Baum Ph.D. Primary Examiner Art Unit 1638 October 28, 2009